- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.03. | DAWNRAYS PHARMA (02348): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025 AND CLOSURE OF REGISTER OF MEMBERS | - | HKEx | ||
| DAWNRAYS PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 27.03. | DAWNRAYS PHARMA (02348): ANNOUNCEMENT OF THE ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2025 | - | HKEx | ||
| 13.03. | DAWNRAYS PHARMA (02348): DATE OF BOARD MEETING | - | HKEx |
3 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ETON PHARMACEUTICALS | 25,000 | +0,08 % | Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS... ► Artikel lesen | |
| LB PHARMACEUTICALS | 26,940 | +4,78 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Reported positive results from potentially registrational Phase 2 trial ofLB-102 in schizophrenia Advanced LB-102 into late-stage development in multiple indications with initiation ofa pivotal Phase... ► Artikel lesen | |
| PMGC | 3,840 | 0,00 % | PMGC Holdings Inc. Announces the Formation of New Subsidiary, NorthStrive Defense Tech to Target High-Growth Defense, Drone and Autonomous Systems Sector | NEWPORT BEACH, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the "Company" or "PMGC") (NASDAQ: ELAB), a diversified holding company, today announced the launch of a new wholly owned... ► Artikel lesen | |
| GRACE THERAPEUTICS | 4,045 | -21,15 % | Grace Therapeutics, Inc.: Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update | FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON... ► Artikel lesen | |
| HARROW | 35,100 | 0,00 % | Harrow, Inc.: Harrow Health, Inc. Reaffirms 2025 Full-Year Revenue Guidance of $270-$280 Million, Marking Another Year of Strong Growth | Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting... ► Artikel lesen | |
| BIOHAVEN | 9,155 | -6,58 % | Biohaven Ltd.: Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results | Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM)... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 74,82 | 0,00 % | BTIG reiterates Bright Minds Biosciences stock rating on seizure treatment potential | ||
| PRF TECHNOLOGIES | 2,530 | 0,00 % | PRF Technologies Ltd.: PRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy | TEL AVIV, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) ("PRF" or the "Company") (formerly "PainReform") today announced that its DeepSolar business unit has entered... ► Artikel lesen | |
| LIPOCINE | 1,940 | 0,00 % | Lipocine Inc.: Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression | In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,095 | 0,00 % | Aquestive reaffirms Q3 2026 NDA resubmission for Anaphylm | ||
| MILESTONE PHARMACEUTICALS | 1,515 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST (etripamil) Nasal Spray for the Treatment of PSVT | FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic... ► Artikel lesen | |
| OMNIAB | 1,540 | 0,00 % | Leerink bestätigt OmniAb mit "Outperform" und Kursziel von 10 US-Dollar | ||
| GENERATE BIOMEDICINES | 12,090 | -11,94 % | Generate Biomedicines Prices IPO At $16/shr | WASHINGTON (dpa-AFX) - Generate Biomedicines, Inc. (GENB) on Thursday priced its initial public offering of 25,000,000 shares of stock at $16 per share, raising gross proceeds of $400 million.The... ► Artikel lesen | |
| ATRIUM THERAPEUTICS | 13,690 | +1,78 % | Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies | Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform
Lead candidates ATR 1072... ► Artikel lesen | |
| MAIA BIOTECHNOLOGY | 1,280 | -3,03 % | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer | Potential breakthrough therapeutic targets $50B+ global immunotherapy market1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a... ► Artikel lesen |
DAWNRAYS PHARMACEUTICAL HOLDINGS LTD gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DAWNRAYS PHARMACEUTICAL HOLDINGS LTD finden Sie auf Wallstreet Online.